SCD and familial hypercholesterolemia: In an obese, metabolically challenged phenotype, reductions in SCD1 through genetic or pharmaceutical inhibition elicit improvements in insulin resistance, glucose clearance, and hypercholesterolemia as well as a reduction in adiposity [18, 31, 37, 40].